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Dissecting the Genetics of Complex Inheritance:
Linkage Disequilibrium Mapping Provides
Insight into Crohn Disease
Heather Elding,1,2 Winston Lau,1,2 Dallas M. Swallow,1 and Nikolas Maniatis1,*
Family studies for Crohn disease (CD) report extensive linkage on chromosome 16q and pinpoint NOD2 as a possible causative locus.
However, linkage is also observed in families that do not bear the most frequent NOD2 causative mutations, but no other signals on 16q
have been found so far in published genome-wide association studies. Our aim is to identify this missing genetic contribution.We apply
a powerful genetic mapping approach to theWellcome Trust Case-Control Consortium and the National Institute of Diabetes and Diges-
tive and Kidney Diseases genome-wide association data on CD. This method takes into account the underlying structure of linkage
disequilibrium (LD) by using genetic distances from LDmaps and provides a location for the causal agent. We find genetic heterogeneity
within the NOD2 locus and also show an independent and unsuspected involvement of the neighboring gene, CYLD. We find associ-
ations with the IRF8 region and the region containing CDH1 and CDH3, as well as substantial phenotypic and genetic heterogeneity for
CD itself. The genes are known to be involved in inflammation and immune dysregulation. These findings provide insight into the
genetics of CD and suggest promising directions for understanding disease heterogeneity. The application of this method thus paves
the way for understanding complex inheritance in general, leading to the dissection of different pathways and ultimately, personalized
treatment.Crohn disease (CD) is a subclassification of idiopathic
inflammatory bowel disease (IBD [MIM 266600]) and has
a disease prevalence of about 100–150 per 100,000 people
in populations of European ancestry.1 It is characterized by
transmural and segmental inflammation, chiefly located in
the ileocecal region of the gastrointestinal tract. There is
disease heterogeneity: Some patients have involvement
of other intestinal regions and, in many cases, extraintesti-
nal manifestations2 as well.
Both CD and ulcerative colitis (UC), the more prevalent
form of IBD, arise primarily from a faulty immune-defense
system of the gut. Twin and family studies suggest that,
unlike most other complex disorders, CD has a high
heritability of 50%–60%3 and an estimated individual
sibling recurrence risk ratio (lS) ranging from 15–30.
4 The
IBD genetics consortia have made progress in mapping
genes involved in CD, and combined genome-wide associ-
ation studies (GWASs) have identified 32 initial suscepti-
bility loci,5 followed by an additional 39.6 Several of these
loci are implicated in other diseases involving inflamma-
tory and immune dysregulation (e.g., PTGER4 [MIM
601586] on chromosome 5p is common to CD, UC,7 and
multiple sclerosis [MIM 126200]8). However, despite the
large number of patients (~22,000 cases),6 this study re-
ported that the 71 loci accounted for only 23.2%6 of the
genetic risk. The well-known problem of ‘‘missing herita-
bility’’ thus applies to CD.
The missing genetic contribution might partly be due to
the fact that current mapping methods miss rare variants
with large effects. However, we suggest it is likely that
both common and rare variants are missed by the single-1Research Department of Genetics, Evolution, and Environment, University C
2These authors contributed equally to this work
*Correspondence: n.maniatis@ucl.ac.uk
DOI 10.1016/j.ajhg.2011.11.006. 2011 by The American Society of Human
798 The American Journal of Human Genetics 89, 798–805, DecembSNP approach, which makes the unrealistic assumption
that one of the SNPs in the genotyping platform either is
the causal agent or is in almost complete linkage disequilib-
rium (LD) with the causal agent. There are also severe prob-
lems associated with the stringent significance levels
required as a result of multiple testing.
Here, we revisit the genome-wide association (GWA)
database in an attempt to shed light on themissing genetic
contribution to CD by applying a powerful multimarker
mapping approach.9 Unlike single-SNP tests, our proce-
dure does not assume that the causal variant is in strong
LD with a particular SNP on the platform. Instead, we
test evidence for association by using a composite likeli-
hood approach in which we use multiple SNPs within a
genomic region. This method gives an estimate of the
most likely causal location by taking into account the
structure of LD in the human genome. For this, we used
genetic distances from LD maps rather than physical loca-
tions in kilobases (kb). We focused on chromosome 16q,
which had previously been reported to show linkage over
an extensive region.10 The discovery in 2001 that variants
in NOD2 (16q12.1 [MIM 605956]), which encodes a pro-
tein required for the pathogen recognition through its
leucine-rich repeats (LRRs), were associated with CD was
a crucial step in providing a direct link between CD and
a genetically altered immune system.11 It was, however,
subsequently reported that there is no direct relationship
between the prevalence of the three most common causal
variants (rs17860491, rs17860492, rs17860493) in the
general population and CD frequency.12 Indeed, NOD2
causal mutations have not been found in all patients.13ollege London, London WC1E 6BT, UK
Genetics. All rights reserved.
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Figure 1. NOD2, CYLD, and Genetic
Heterogeneity
(A) Analysis of all patients (unstratified data); SNP
data are grouped in two separate windows,
covering either NOD2 or CYLD. The vertical lines
are the estimated locations (S^) for the windows
including NOD2 alone and CYLD alone. The LD
map, which plots LDUs (y axis) against physical
distance (x axis), is shown for the region sur-
rounding the estimates of S^.
(B) Stratified data are shown for carriers and
noncarriers of the most frequent NOD2 causal
variants. (B) includes SNPs for both genes (the
NOD2 and CYLD window). See text for details
on the stratification procedure. The SNPs
rs17860491, rs17860492, and rs17860493 corre-
spond to the reported functional SNPs in
NOD2. This figure also depicts the position of
a putative enhancer (see text).Although this finding is not surprising in complex inheri-
tance, linkage was still observed in families who did not
bear the most frequent NOD2 mutations.14 However, no
other signals on 16q have been found so far in published
GWASs. To add to the complexity, NOD2 mutations are
associated with ileal CD but not with perianal or colonic
disease.15
The strong evidence of linkage on 16q cannot, in our
view, be fully accounted for by the one gene, NOD2,
upon which so much attention has been focused. Indeed,
with our method we found several distinct association
signals of high significance on chromosome 16q alone.
Here, we report three of these regions that we have studied
in detail. Each emerges from the Wellcome Trust Case
Control Consortium (WTCCC) data and, quite indepen-
dently, from the NIDDK database, which contains infor-
mation on Jewish ancestry as well as detailed phenotypic
data. We analyzed 1,698 cases for CD and 2,948 controls
from the GWA scan of the UK WTCCC study16 by using
the Affymetrix 500K array. Half of the ~3,000 nationallyThe American Journal of Humaascertained controls came from the 1958
British birth cohort collection and the
remainder from the UK Blood Services
collection of common controls.16 The cases
were confirmed to be patients of any sub-
type of CD via endoscopic, radiological
procedures and histopathological criteria.
The cases were not specifically enriched
for early age of onset or family history,
and they were from a variety of IBD clinics.
For the replication study, we analyzed 813
North American patients with CD and 947
controls made available by the NIDDK
IBDGC. The NIDDK IBDGC GWA scan
was based on the Illumina HumanHap300
array,17 which has a smaller sample size
and a set of SNPs that overlap only partially
with the WTCCC SNP array. However, the
NIDDK has more phenotypic data thantheWTCCC and includes information on the involvement
of other intestinal locations. Details are available in other
reports.16,17
Our approach uses genetic locations from a high-resolu-
tion LD map that can describe the underlying structure of
LD. We can visualize LD maps18 by plotting marker loca-
tions in LD units (LDU) against distances in kilobases
(kb), which demonstrates the nonlinear relationship
between physical distance and LD. These metric genetic
maps are analogous to linkage maps in cM.19 A high-
density LDU map for the whole of chromosome 16 was
constructed with the CEU (Utah residents ancestry from
northern and western Europe from the CEPH collection)
phase II data from the HapMap Project.20 Figure 1A shows
the ‘‘block-step’’ structure of a 225 kb region that flanks
NOD2. Blocks of conserved LD (horizontal line, Figure 1A)
are areas of reduced haplotype diversity, whereas steps
represent LD breakdown due to recombination (i.e.,
cross-over profiles agree with LDU patterns).21 We also
constructed LDU maps for the three gene regions fromn Genetics 89, 798–805, December 9, 2011 799
Table 1. Association Statistics and Estimated Location of the Causal Variation for Three Different Windows Covering NOD2 and CYLD,
in Relation to the Locations on the Human Genome Sequence
Data Windowa Cases c21
b p Value Estimated Location (kb) 95% Confidence Interval (kb)
WTCCC NOD2 1,698 62.6 3 3 1015 49,306.7 49,265–49,324
NIDDK NOD2 813 37.1 1 3 109 49,306.7 49,265–49,396
WTCCC CYLD 1,698 54.4 2 3 1013 49,403.8 49,397–49,408
NIDDK CYLD 813 12.5 4 3 104 49,404.0 49,404–49,408
The coordinates for NOD2 and CYLD are 49,289–49,324 and 49,334–49,393 kb, respectively.
a Window with marker information covering NOD2 or the adjacent window covering CYLD.
b A c2 determined via the composite-likelihood method for each window.the latest HapMap III CEU data and the WTCCC controls,
but all maps yielded the same LDU patterns (results not
shown). However, we used the HapMap phase II data to
obtain genetic distances in LDU because their estimation
is based on a higher resolution as a result of a denser SNP
coverage than the HapMap III data. The methodology for
constructing LDU maps is based on the Male´cot model,
which describes the decline of LD as a function of
distance18 and is an extension of earlier work.22
The entire 16q was divided into nonoverlapping
windows on the basis of the LDU map, and each window
had a minimum length of 10 LDU and a minimum of 30
SNPs. For each window, the multimarker method9 re-
turned a p value from composite test statistics and an esti-
mated location of the causal variant (S^). The association
mapping that was applied for each window was based on
the same Male´cot model used for constructing LDU
maps, but we modeled the decline of affection-status-by-
SNP association as a function of genetic distance in LDU
by using HapMap LDU locations.9 We tested each window
for an association with CD by using composite likelihood
(L) that combined information from all single-SNP tests
within each window and avoided undue multiple testing
correction. The significance for each window is based on
an F statistic, which we formulated by comparing L from
the null model, which assumes no association, with L
from the alternative, where the S^ is estimated iteratively.
The p value takes into account the different degrees of
freedom for each window. For convenience, the F statistic
was converted to c2 with 1 degree of freedom.9 The 95%
confidence interval (CI) for the estimated location S^ was
obtained as S^ 5 t SE, where t is the tabulated value of
Student’s t test and SE is the standard error of the parameter
S^. We obtained the predicted estimates of S^ and 95% CIs by
fitting the LDU genetic distances, given that this approach
increases the power of association.9 For convenience, we
converted these estimates back to kb (NCBI35 assembly)
by using linear interpolation of the two flanking SNPs in
HapMap. When S^ is in an LD block (horizontal line), all
markers within that block have the same LDU location.
In such cases, we took themidpoint of that block as an esti-
mate of S^ in kb. The CIs measured in kb cannot be symmet-
rical because of the ‘‘block-step’’ structure of the human
genome. Other details are given by Maniatis et al.,9 who800 The American Journal of Human Genetics 89, 798–805, Decembprovide evidence of the power and resolution of this
approach over single SNPs. A more recent study on
a disease case showed similar results.23
Initially, using the WTCCC data, we identified three
major signals on chromosome 16q in the regions of
NOD2 and CYLD (MIM 605018), CDH3 (MIM 114021)
and CDH1 (MIM 192090), and IRF8 (MIM 601565)
(Table 1). We then used the NIDDK GWA data to replicate
this study. Table 1 and Figure 1A show the significance
and estimated locations (S^) for the genomic region that
harbors NOD2 and CYLD for both datasets. Two indepen-
dent signals of association were mapped to NOD2 and
CYLD. An analysis of the window that only included
marker information from NOD2 yielded a highly sig-
nificant association with CD for the WTCCC dataset;
this association was replicated with the NIDDK dataset.
The estimated (S^) location was identical for both datasets
(49,306.7) and was within an LDU block that spans
16 kb. The block includes exons 4 and 8, which harbor
two of the most frequent causative variants (rs17860491-
R702W and rs17860492-G908R, respectively) within
NOD2. The third most frequent variant (rs17860493-
1007fs) is on a neighboring LD block and has a slightly
different LDU location (see LDU block, Figure 1A). The
analysis of the WTCCC data for the CYLD window yielded
an estimated location 11 kb downstream of the gene
(Figure 1A). This signal was replicated with the NIDDK
data and had an estimated location 234 base pairs down-
stream of the WTCCC S^.
Figure 1A shows the estimates of S^ for the two different
NOD2 and CYLD windows and datasets. For both datasets,
the CYLD window was significantly associated with CD
(2 3 1013 and 4 3 104 for WTCCC and NIDDK, respec-
tively, Table 1). The lower significance in the NIDDK
data, as compared to the WTCCC result, is probably not
only due to the difference in sample size but also to the
fact that WTCCC included any subtype of CD and not
just the ileal form of the condition. The 95% CI for the
CYLD window is very narrow (8.3 kb) for both datasets
because S^ is within a region of LD breakdown caused by
a recombination hot spot. Remarkably, this location is
approximately 2 kb away from a predicted enhancer region
(coordinates: 49,405.9–49,407.2 kb), which is within the
95% CI (Table 1). This ‘‘enhancer element 85’’ has beener 9, 2011
Table 2. Association Statistics and Estimated Location of the
Causal Variation for Three Different Windows Covering NOD2 and
CYLD, in Relation to the Locations on the Human Genome Sequence
Data Windowa Cases c21
b p Value
Estimated
Location (kb) Signal
WTCCCc
AA NOD2 and CYLD 805 46.0 1 3 1011 49,403.8 CYLD
AG NOD2 and CYLD 665 124.6 6 3 1029 49,306.7 NOD2
GG NOD2 and CYLD 199 82.8 9 3 1020 49,306.7 NOD2
NIDDKc
CC NOD2 and CYLD 482 13.5 2 3 104 49,403.8 CYLD
CT NOD2 and CYLD 266 60.5 7 3 1015 49,306.7 NOD2
TT NOD2 and CYLD 60 103.3 3 3 1024 49,306.7 NOD2
The coordinates for NOD2 and CYLD are 49,289–49,324 and 49,334–
49,393 kb, respectively.
a Window with marker information from both genes.
b A c2 determined via the composite-likelihood method or each window.
c Data stratified on the basis of the AA, AG, and GG genotypes for the
rs2076756 SNP from the WTCCC data (49,314.4 kb) and CC, CT, and TT
genotypes for the rs5743289 SNP from the NIDDK data (49,314.3 kb).identified in a bioinformatics study that combined se-
quence conservation and functional studies.24
These results show that the NOD2 region is more com-
plex than was previously thought. The two different S^
locations within the region containing NOD2 and CYLD
are an indication of the existence of different risk genes
in different patients (genetic heterogeneity). We further
investigated the relationship of these two genes by
analyzing a window that included marker information
from both NOD2 and CYLD and by stratifying the data
(Figure 1B). The three frequent causal NOD2 muta-
tions11,12,25 were not included in the genotyping platforms
for either WTCCC or NIDDK, and we could not directly
identify which of those patients bore the mutations. For
genetic stratification with respect to carrier status for the
most common NOD2 mutations, we used the SNP
rs2076756 in the WTCCC dataset (G was the minor allele
and had a frequency of 0.24 in controls and 0.32 in cases)
and rs5743289 in the NIDDK dataset (T was the minor
allele and had a frequency of 0.17 in controls and 0.24
in cases). The stratification by SNP separated, as far as
possible, the patients with NOD2 mutations from those
without. This procedure was feasible because the two
SNPs (100 bp apart) were in complete LD and were in
a region of conserved LD that contained the three NOD2
mutations (see LDU map in Figure 1A; also previously re-
ported for rs207675626). The group that included all the
carriers of the disease-associated allele (carriers were indi-
viduals who were heterozygous or homozygous for the
minor allele, i.e., they had AG/GG or CT/TT genotypes
for the rs2076756 [WTCCC] or rs5743289 [NIDDK] SNPs,
respectively) yielded much higher significance levels
than before, even though the number of patients was
much smaller than that of the full dataset (Table 2). This
finding gives evidence that these two groups of patientsThe Americando represent themajority of cases with the functional caus-
ative NOD2 mutations. In addition, S^ was within NOD2,
despite the fact that we analyzed both genes in the same
window (NOD2 and CYLD window, Table 2, Figure 1B).
Using the unstratified data showed that the position of S^
(49,306.7 kb) was exactly the same as for the NOD2
window in Figure 1A.
The analyses of the noncarrier cases for the WTCCC (AA
for rs2076756) and the NIDDK (CC for rs5743289)
produced essentially identical results; both pointed toward
a location approximately 11 kb downstream of CYLD
(Table 2, Figure 1B). This genetic stratification reveals
heterogeneity among patients with CD and indicates
that CYLD plays a larger role in patients who do not carry
NOD2 functional mutations.
NOD2 interacts with nuclear factor-lB (NF-lB) by
signaling in a complex way, which includes ubiquitinyla-
tion.27 Interestingly, CYLD is a deubiquitinating (ubiqui-
tin-removing) enzyme that has been shown to regulate
cell proliferation, cell survival, and inflammatory
responses28 and that is also involved in NF-lB signaling.
Dysregulation of NF-lB signaling leads to a defective
immune system, causing an immunodeficient or autoim-
mune phenotype, depending on whether NF-lB function
is impaired or persistent.29 CYLD is important in immune
homeostasis because it prevents the spontaneous activa-
tion of NF-lB in peripheral T and B lymphocytes. The
peripheral T cells fromCYLD-deficient mice have increased
sensitivity and a heightened response to T cell receptor
(TCR) stimulation; this heightened response leads to spon-
taneous inflammation in the colon30 and colitis-associated
tumorigenesis.31 Inflammation is the major underlying
phenotype of CD, and some CD patients develop colon
cancer at a later stage in life. Furthermore, genome-wide
cDNAmicroarray analysis demonstrates that CYLD expres-
sion is downregulated in CD.32
The WTCCC dataset contains patients who have any
subtype of CD (the database does not include subclassifica-
tion of the disease). On the other hand, the NIDDK data-
base contains additional disease-related information—
that on a possible extraileal intestinal involvement in
particular—and also classifies the patients and controls
according to ancestry (Jewish or non-Jewish). Given that
there was a prior expectation of genetic differentiation
across these categories,33 we exploited this extra informa-
tion to stratify the analyses of the CDH3-CDH1 and IRF8
regions.
Table 3 shows the significance and estimated locations
we found for the signals in the IRF8 window and the
window containing CDH3 and CDH1. For the analyses
of the WTCCC data, both windows were significantly
associated with CD (1 3 108 and 4 3 109, respectively).
These two signals were not initially replicated with the
NIDDK GWA scan; however, when we reanalyzed the
windows on the basis of a subset of the data by using
phenotypic information given by the NIDDK IBDGC,
they showed significant association. This subset includedJournal of Human Genetics 89, 798–805, December 9, 2011 801
Table 3. Association Statistics and Estimated Location of the Causal Variation for Two DifferentWindows Covering CDH3, CDH1, and IRF8,
in Relation to the Locations on the Human Genome Sequence
Data Window Cases c21
a p Value Estimated Location (kb) 95% Confidence Interval (kb)
WTCCC CDH3,CDH1 1,698 32.6 1 3 108 67,303.7 67,239–67,393
NIDDKb CDH3,CDH1 315 6.2 1 3 102 67,303.7 67,241–67,393
WTCCC IRF8 1,698 34.7 4 3 109 84,539.8 84,539–84,541
NIDDKb Jewishc IRF8 38 20.9 5 3 106 84,515.7 84,506–84,519
Non-Jewishc IRF8 277 5.3 2 3 102 84,515.7 84,492–84,519
The coordinates for CDH3, CDH1, and IRF8 are 67,236–67,290, 67,329–67,427, and 84,490–84,514 kb, respectively.
a A c2 determined via the composite-likelihoodmethod for each window. Note that the 95%CIs for IRF8 for the UK and North American data are nonoverlapping,
suggesting heterogeneity of the location of the causative change, i.e., allelic heterogeneity.
b Ileal CD with the involvement of at least one other extraileal intestinal location.
c 432 Jewish and 515 non-Jewish controls were used for these analyses.patients who had ileal CD and an involvement of at least
one extraileal intestinal location, i.e., jejunal, colorectal,
or perianal. We replicated the WTCCC signal within the
CDH3 and CDH1 window by using this subset of the
NIDDK data, despite the much smaller number of cases
(Table 3). Thus, phenotypic heterogeneity is clearly impor-
tant. For both GWA scans, the estimated location S^ for
the former window was between CDH3 and CDH1, within
an LDU block spanning 65 kb (Figure 2). The causal locus
could be anywhere within this block, which included the
30 region of CDH3 through CDH1 intron 2 (Figure 2). Also
within this block was a functional promoter SNP,
rs1626034 (Figure 2), that had previously been associated
with postinfectious IBD.35 CDH3 and CDH1 encode
cadherin proteins that participate in cell recognition,
signaling, morphogenesis, and tumor progression. CDH1
encodes an epithelial cadherin (E-cadherin) that is ex-
pressed in the intestine and which has essential functions
in intestinal homeostasis.36 The loss of E-cadherin expres-
sion leads to apoptosis and cell shedding and to disruption
of the maturation of paneth and goblet cells, which are
important to the innate immune system and to microbial
defense.36 E-cadherin helps to maintain the intestinal
epithelial defense system, and reduced CDH1 expression802 The American Journal of Human Genetics 89, 798–805, Decembis a feature of CD and UC patients with an inflamed intes-
tinal epithelium.37 A genome-wide linkage analysis of
CD reported evidence of linkage on 16q in families that
did not carry the NOD2 mutations.14 Notably, CDH3 and
CDH1 are at that linkage peak. However, GWASs and
meta-analyses of CD did not detect these genes, despite
the large number of samples and imputations based on
the latest HapMap samples. A GWA scan on UC, on the
other hand, has recently reported CDH1 as a susceptibility
locus38 and has found that the most significant SNP for
UC is 180 kb upstream of the gene. Here, we demonstrate
that the most likely location of the causal variant is within
an interval that is flanked by CDH3 and CDH1. CDH1 was
also detected in a GWA meta-analysis of colorectal cancer
(MIM 114500), and the reported SNPs fall within our
confidence interval.39 CDH3, which encodes placental-
cadherin (P-cadherin), is also implicated in colorectal
carcinomas.40
For the IRF8 window, the WTCCC data yield an S^
location 29 kb downstream of the gene, within a small
block that is flanked by LD breakdown (Figure 3). IRF8
encodes the transcription factor also known as interferon
consensus sequence-binding protein, which plays a nega-
tive regulatory role in cells of the immune system. TheFigure 2. Localization within the CDH3 and
CDH1 Region
The LD map, which plots HapMap LDUs (y axis)
against kb (x axis), is shown for the region
surrounding S^. The red vertical arrow is the esti-
mated location S^ for both data sets, but because
of the very long LD block, the causal location(s)
could reside anywhere in this block. The
rs16260 is a functional SNP within this block
and is located 365 nucleotides upstream of the
transcription start site for CDH1. *NIDDK data
only contain ileal CD with the involvement of
at least one extraileal intestinal location.
er 9, 2011
Figure 3. Localization within the IRF8 Region
The LD map, which plots HapMap LDUs (y axis)
against kb (x axis), is shown for the region
surrounding the S^. The red vertical arrow is the
estimated location S^. *NIDDK data only contain
ileal CD with an involvement of at least one ex-
traileal intestinal location. Two SNPs have been
identified for UC and MS in GWA meta-analyses.analysis of the NIDDK data for patients with any extraileal
intestinal involvement showed a signal that is 1.7 kb
downstream of IRF8 within a region of LD breakdown
(Figure 3). This signal was revealed to be significant after
we further separated the data into Jewish and non-Jewish
patients. The Jewish data alone yielded a substantially
higher significance than the non-Jewish data, although it
was derived from only 38 cases and 432 controls as
opposed to 277 cases and 515 controls for the non-Jewish
data (Table 3). This effect was only observed for the IRF8
window but shows the importance of considering
ancestral heterogeneity. These two NIDDK datasets yielded
essentially identical S^ locations. The 95% CIs for both the
Jewish and non-Jewish data included part of the IRF8 gene
and had an estimated location 24 kb upstream of the
WTCCC signal (Table 3, Figure 3), further suggesting allelic
heterogeneity. A recent meta-analysis of GWA data on
multiple sclerosis, an immune-dysregulation condition,
identified a marker SNP (rs17445836) 61 kb away from
IRF8 (Figure 2). Another study on UC has identified
a SNP (rs16940202) 58 kb downstream of IRF8. IRF8
expression is crucial in bone metabolism: IRF8-deficient
mice display extensive osteoporosis, one of the extraintes-
tinal manifestations associated with CD.41
Here, by using a multimarker genetic-mapping approach
on available WTCCC data, we found three additional
significant signals of association with CD, and all three
signals were replicated with the NIDDK GWA scan.
Furthermore, we show that there is substantial heteroge-
neity in the NOD2 region and demonstrate the indepen-
dent involvement of the neighboring gene, CYLD. We
also show two additional signals within the IRF8 gene
region and the region containing CDH3 and CDH1. The
analytical method used here avoids undue Bonferroni
correction. Significance for all analyses of the WTCCC
data passed the Bonferroni threshold for all 98 windows
tested. These signals were replicated with the NIDDK
data, which has a smaller sample size and less SNPThe American Journal of Humacoverage. Using the same method but ex-
pressing the distances in kb instead of
LDU yielded a lower c21 (data not shown),
which agrees with the findings of previous
studies.42 Also, a kb map provides poorer
estimates of S^ than does an LDU map
because it does not consider the LD struc-
ture. Our analysis with LDU maps provides
insight into the genetic and phenotypicheterogeneity of CD and might be a promising way to
study other frequent and complex diseases.
In recent years, the emphasis of genetic studies has
shifted from hypothesis-driven research to GWASs, largely
as a result of technological advancement. This shift
has been very expensive and has been criticized for its
slow progress. Even so, expensive data are now becoming
available, and here, we use an approach to extract more
information from such data. We find that complex inheri-
tance can be dissectedmore effectively than before and also
that detailed records of disease phenotype and ancestry
are more useful than larger datasets. Our approach brings
localization—as opposed to regions—and greater informa-
tion to mapping and to the understanding of the disease
phenotype. It indicates that regulatory regions such as
enhancers are often important43,44 and calls into question
the current trend of focusing on exome sequencing.
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